Trump's Sights Set On Payers And Pharmas, But Medtechs Must Not Be Complacent
It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.
You may also be interested in...
Republican action to ram an Affordable Care Act replacement bill through two House committees overnight, without a Congressional Budget Office score and over the objections of powerful health-care interests, appears to be undermining support for the American Health Care Act, threatening ultimate congressional passage of the bill and its device-tax repeal provision.
The return of a Republican president to power in last month's US elections showed – for the second time in 2016 – that punditry can be misleading and opinion polls do not always equate with reality. With just a few weeks to President Trump's inauguration, ZS Associates' Brian Chapman gives an early appraisal of how the new administration might view the health care brief in general and the medtech industry in particular.
The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.